Chronic sleep disturbances, associated with cardiometabolic diseases, psychiatric disorders and all-cause mortality 1,2 , affect 25-30% of adults worldwide 3 . Although environmental factors contribute substantially to self-reported habitual sleep duration and disruption, these traits are heritable 4-9 and identification of the genes involved should improve understanding of sleep, mechanisms linking sleep to disease and development of new therapies. We report single-and multiple-trait genome-wide association analyses of self-reported sleep duration, insomnia symptoms and excessive daytime sleepiness in the UK Biobank (n = 112,586). We discover loci associated with insomnia symptoms (near MEIS1, TMEM132E, CYCL1 and TGFBI in females and WDR27 in males), excessive daytime sleepiness (near AR-OPHN1) and a composite sleep trait (near PATJ (INADL) and HCRTR2) and replicate a locus associated with sleep duration (at PAX8). We also observe genetic correlation between longer sleep duration and schizophrenia risk (r g = 0.29, P = 1.90 × 10 −13 ) and between increased levels of excessive daytime sleepiness and increased measures for adiposity traits (body mass index (BMI): r g = 0.20, P = 3.12 × 10 −9 ; waist circumference: r g = 0.20, P = 2.12 × 10 −7 ).
Rather than being 'secondary' , disordered sleep may have an important role in the etiology and maintenance of physical and mental health 1, 2 . Heritability has been estimated at ~40% for sleep duration 4,6-8 , 25-45% for insomnia 9 and 17% for excessive daytime sleepiness 9 , but few genetic factors are known. A Mendelian mutation in BHLHE41 (encoding p.Pro385Arg) associated with short sleep duration has been identified and was confirmed in mouse models 10 . Genome-wide association studies (GWAS) for sleep duration have been reported [11] [12] [13] [14] , but only an association at the PAX8 locus reached genome-wide significance and was confirmed across ancestry groups 12 . There are several reported loci associated with restless legs syndrome (RLS) and narcolepsy, but no robust genetic loci have been associated with insomnia symptoms or excessive daytime sleepiness 15, 16 .
We and others have performed a GWAS for chronotype in the UK Biobank 17, 18 and a 23andMe participant sample 19 . To identify genetic variants that contribute to self-reported sleep duration, insomnia symptoms and excessive daytime sleepiness and link them with other conditions, we performed GWAS using phenotype measures in UK Biobank participants of European ancestry. Variation in sleep duration, insomnia symptoms and excessive daytime sleepiness was significantly associated with age, sex, principal components of ancestry, genotyping array, depression, psychiatric medication use, self-reported sleep apnea and BMI (Supplementary Table 1) , as previously reported [20] [21] [22] [23] . Together, age, sex and principal components explained 0.4%, 3.0% and 1.3% of variation in sleep duration, insomnia symptoms and excessive daytime sleepiness, respectively. Strong and significant pairwise phenotypic correlation was seen between the Genome-wide association analyses of sleep disturbance traits identify new loci and highlight shared genetics with neuropsychiatric and metabolic traits traits overall and within each sex, with limited correlation observed with chronotype ( Fig. 1 and Supplementary Fig. 1 ).
We performed GWAS analyses of sleep duration, insomnia symptoms and excessive daytime sleepiness using linear/logistic regression adjusting for age, sex, ten principal components and genotyping array. We identified 9 genome-wide significant (P < 5 × 10 −8 ) and 14 suggestive (P < 5 × 10 −7 to P = 5 × 10 −8 ) loci (Fig. 2, Table 1 and Supplementary Figs. 2 and 3) . For sleep duration (n = 111,975), the strongest association was observed at the PAX8 locus (rs62158211[T]: β (s.e.) = 2.34 (0.30) min/allele, P = 4.7 × 10 −14 , effect allele frequency (EAF) = 0.213; Fig. 2a) , confirming a previously reported association (r 2 = 0.96, D′ = 1 to lead SNP rs1823125 in 1000 Genomes Project CEU (European-ancestry) individuals) 12 . For insomnia symptoms (n = 32,155 cases and 26,973 controls), we observed significant associations within MEIS1 (rs113851554[T]: odds ratio (OR) (95% confidence interval (CI)) = 1.26 (1.20-1.33), P = 9.1 × 10 −19 , EAF = 0.057; Fig. 2b) , a homeobox gene implicated in motor neuron connectivity in Drosophila melanogaster 24, 25 , retinal and lens development in mouse 26 and substance P expression in the amygdala in humans 27 ; near TMEM132E (rs145258459[C]: OR (95% CI) = 1.23 (1.13-1.35), P = 2.1 × 10 −8 , EAF = 0.983; Fig. 2c) , which belongs to a gene family whose members have roles in brain development 28 , panic/anxiety 29 and bipolar disorder 30 , suggesting a link between insomnia symptoms and an underlying broader sensitivity to anxiety and stress; and near CYCL1 (rs5922858 [G] : OR (95% CI) = 1.12 (1.07-1.16), P = 1.28 × 10 −8 , EAF = 0.849; Fig. 2d ), a locus previously associated (P = 1 × 10 −6 ) with alcohol dependence comorbid with depressive symptoms 31 . Sex-stratified analyses identified an additional female-specific signal near TGFBI (rs3792900 [C] : OR (95% CI) = 1.10 (1.07-1.14), P = 2.16 × 10 −8 , EAF = 0.470; [33] [34] [35] . For excessive daytime sleepiness (n = 111,648), we identified a signal near the androgen receptor gene AR (rs73536079[T]: β (s.e.) = 0.634 (0.115), P = 3.94 × 10 −8 , EAF = 0.002; Fig. 2e) , with no sex-specific effects. Secondary analyses after additional adjustment for depression or BMI identified a signal near ROBO1 (depression adjustment n = 107,440; rs182765975[T]: β (s.e.) = 0.099 (0.018), P = 3.33 × 10 −8 , EAF = 0.003; Table 1 and Supplementary Fig. 3o ), which encodes a neuronal axon guidance receptor previously implicated in dyslexia 36 , and a signal near another member of the TMEM132 family, TMEM132B (BMI adjustment n = 75,480; rs142261172[A]: β (s.e.) = 0.106 (0.018), P = 9.06 × 10 −9 , EAF = 0.004; Table 1 and Supplementary Fig. 3p) Table 4 ).
The leading associations overlap interesting candidate genes whose expression is enriched in hypocretin-expressing neurons in mice and zebrafish 37, 38 , that are differentially expressed in sleepdeprived rats 39 and/or that regulate sleep in Drosophila 40 . Credible set analyses 41 highlighted a number of potential causal variants at each locus (Table 1) , and future experimental studies will be necessary to characterize the functions of these variants in regulating sleep traits. Bioinformatic annotations 42 offer an initial opportunity for in silico functional interpretation of the variants ( Supplementary Fig. 5 and Supplementary Table 5 ). For example, multiple variants for all three traits are predicted to disrupt binding of FOXP1, a neural transcriptional repressor implicated in intellectual disability, autism and language impairment 43 . Interestingly, the locus associated with sleep duration encompassing PAX8 is adjacent to the only chromosomal fusion site that arose since the divergence of humans from other hominids ~5 million years ago 44, 45 , and the new genomic structure created by this unique evolutionary history may have a causal role in sleep duration. Pathway analysis 46 of significant and suggestive loci identified enrichment of genes associated with immune, neurodevelopmental, pituitary and communication disorders (P < 0.01) and genes enriched for binding sites for the stress-responsive transcription factor heat shock factor 1 (HSF1) and the endoplasmic reticulum stress-and unfolded-protein-responsive transcription factor HERPUD1 (Supplementary Tables 6 and 7) .
Aside from the lead SNPs in the PAX8 region and a variant in the DRD2 region 47 for sleep duration, we found limited evidence of association for previously published candidate gene or GWAS signals (P meta < 5 × 10 −5 ; Supplementary Table 8) or for regions encompassing core clock genes (Supplementary Fig. 6 ). Our findings for the GWAS on sleep duration largely overlap with those of Jones et al. 18 , despite differences in exclusion criteria and analytical approach. In particular, our study excluded shift workers (n = 6,557), sleep medication users (n = 1,184) and first-to third-degree relatives (n = 7,980), whereas the linear mixed-model analyses by Jones et al. 18 included these populations, leading to a larger sample size (n = 127,573). Likely because of this increased power, Jones et al. 18 identified two additional signals at VRK2 that did not attain genome-wide significance in our study (rs1380703 l e t t e r s l e t t e r s
Trait heritability calculated as the proportion of trait variance due to additive genetic factors measured here (observed-scale SNP heritability, h 2 (s.e.)) was 10.3% (0.006%) for sleep duration, 20.6% (0.011%) for insomnia symptoms and 8.4% (0.006%) for daytime sleepiness (BOLT-REML variance-components analysis 48 ). LD score regression analysis 49 confirmed no residual population stratification (intercept (s.e.): sleep duration, 1.012 (0.008); insomnia symptoms, 1.003 (0.008); excessive daytime sleepiness, 1.005 (0.007)). Tests for enrichment of heritability by functional class using an LD score regression approach 50 identified excess heritability across active transcriptional regions for insomnia symptoms and across genomic regions conserved in mammals for all three sleep traits. Consistent with these findings, heritability enrichment in conserved regions was seen for traits demonstrating significant genetic correlation with sleep ( Fig. 3 and Supplementary Table 9) .
Sleep duration, insomnia symptoms, excessive daytime sleepiness and chronotype are significantly correlated, both at the phenotype and genetic levels ( Fig. 1) , with greater pairwise correlations in males than in females (Supplementary Fig. 1) . Thus, to find loci common to sleep traits, we performed a multiple-trait GWAS 51 . We identified two new association signals near HCRTR2 and PATJ (INADL) and found that PAX8 and MEIS1 associations influenced multiple sleep traits (Fig. 2, Table 2 and Supplementary Fig. 7 ). HCRTR2 encodes hypocretin receptor 2, the primary receptor of two receptors for wake-promoting orexin neuropeptides 52 involved in narcolepsy and regulation of sleep. Notably, the minor allele at rs3122163 (C) showed subthreshold association with shorter sleep duration and morningness chronotype, suggesting gain of function, but no association with insomnia symptoms. Assessment of objective sleep measures and functional and physiological follow-up should yield important insights into orexin receptor signaling, a pathway important for the pharmacological treatment of narcolepsy 53 and insomnia 54 . PATJ encodes a membrane protein involved in the formation of tight junctions and is implicated in photoreception in mice and Drosophila 55, 56 . The INADL protein is reported to interact with HTR 2A (ref. 57 ), a serotonin receptor with a known role in sleep regulation 58, 59 .
Our strongest association for insomnia symptoms fell within MEIS1, a locus previously associated with RLS in GWAS 60 . Our lead SNP, rs113851554, and the correlated 3′ UTR variant rs11693221 (pairwise r 2 = 0.69, D′ = 0.90 in 1000 Genomes Project European (EUR) individuals) represent the strongest known genetic risk factor for RLS and were identified in MEIS1 sequencing studies 61, 62 following up the original RLS GWAS signal (rs2300478) 60, 63 . Conditional analysis suggests that only one underlying signal, detected by the lead SNP rs113851554 in our GWAS, explains the association of all three SNPs with insomnia symptoms (Supplementary Fig. 8 and Supplementary Table 10 ). To further investigate the extent of overlap between RLS and insomnia symptoms, we tested a weighted genetic risk score (GRS) for RLS 64, 65 and found that it was also associated with insomnia symptoms with concordant direction of allelic effects (OR (95% CI) = 1.06 (1.05-1.07) per RLS risk allele, P = 1.17 × 10 −21 ; Table 11 ). Interestingly, recent data indicating that thalamic glutamatergic activity is increased in RLS provide evidence of an underlying propensity for hyperarousal in RLS 66 , which is also a core feature of insomnia. Future analyses of pairwise bidirectional causal effects for all three traits will be necessary to determine whether shared genetic associations correspond to causality, partial mediation or pleiotropy.
Supplementary Table 11). Weighting of the RLS GWAS alleles by SNP effect on periodic limb movements (PLMs) did not substantially alter the overall results (Supplementary
Strong epidemiological associations of sleep duration, insomnia symptoms and daytime sleepiness have been observed with disease traits, but the extent to which the underlying genetics are shared is unknown. Therefore, we tested for genome-wide genetic correlation between findings from our sleep GWAS and those from publicly available GWAS for 20 phenotypes spanning a range of cognitive, neuropsychiatric, anthropometric, cardiometabolic and autoimmune traits using LD score regression 67 (Fig. 4 and Supplementary Table 12) .
Genetic correlations demonstrated a strong biological link between longer sleep duration and risk of schizophrenia (r g = 0.29, P = 1 × 10 −13 ), as suggested by previous reports 18, 47, 68 . Furthermore, a schizophrenia GRS (96 variants) was associated with longer sleep duration (β (s.e.) = 1.44 (0.36) min/allele, P = 2.56 × 10 −4 ) (interquartile range = 2.3 h), although a variety of sleep behaviors are seen in patients with schizophrenia [69] [70] [71] . Significant genetic correlation between low birth weight and longer sleep duration (r g = −0.27, P = 1 × 10 −4 ) may reflect shared links between genetically determined insulin secretion or action pathways underlying fetal growth 72, 73 and long sleep duration. In support of this hypothesis, significant genetic correlation was observed by Jones et al. 18 between oversleeping and both fasting insulin and risk of type 2 diabetes in UK Biobank. Genetic correlation between sleep duration and Crohn's disease risk (r g = 0.18, P = 1 × 10 −3 ) is also consistent with epidemiological observations 74 .
Significant genetic correlation was also found between increased insomnia symptoms and major depression, adverse glycemic traits, increased adiposity and fewer years of education and between excessive daytime sleepiness and increased adiposity (all P < 1 × 10 −3 ), further Error bars represent the 95% confidence intervals around the estimates. We tested 25 functional annotations; annotations passing the multiple-testing significance threshold (P < 0.005) are shown. For context, the average enrichment across functional annotation categories is shown for nine traits with significant genetic correlation to at least one sleep trait (GWAS traits correlated with sleep; including GWAS for BMI, waist circumference, birth weight, depression, educational attainment, three glycemic traits in non-diabetics and schizophrenia) and for five traits with no significant genetic correlation to any sleep trait (GWAS traits uncorrelated with sleep; including GWAS for Alzheimer disease, type 2 diabetes, autism, rheumatoid arthritis and height). H3K9, histone H3 lysine 9.
l e t t e r s l e t t e r s highlighting biological overlap of sleep traits with metabolic traits, psychiatric traits and educational attainment 17 . In support of this overlap, studies have shown that experimentally suppressing slow-wave sleep leads to decreased insulin sensitivity and impaired glucose tolerance 75, 76 . Notably, a GRS for fasting insulin was not significantly associated with insomnia symptoms (7 SNPs, OR (95% CI) = 1.01 (0.99-1.03), P = 0.51). Finally, consistent with a well-established but poorly understood link between excessive daytime sleepiness and obesity 77, 78 , a GRS for BMI was associated with excessive daytime sleepiness (95 SNPs, β (s.e.) = 0.002 (0.0004) sleepiness category/allele, P = 1.67 × 10 −4 ) but not with insomnia symptoms (OR (95% CI) = 1.00 (0.998-1.003), P = 0.73).
Moving forward, replication and systematic testing of genetic correlations in larger samples will be needed. Notably, genetic correlation testing between insomnia and RLS should be examined but was not possible here because RLS consortium GWAS results were not available. Additionally, identifying causal relationships between genetically correlated traits may be difficult, and findings using Mendelian randomization approaches will need cautious interpretation given potential selection biases in UK Biobank [79] [80] [81] .
In summary, in a GWAS of sleep traits, we identified new genetic loci that point to previously unstudied variants that might modulate the hypocretin-orexin system and retinal development and influence genes expressed in the cerebral cortex. Furthermore, genome-wide analysis suggests that sleep traits have underlying genetic pathways in common with neuropsychiatric and metabolic diseases. This work should advance understanding of the molecular processes underlying sleep disturbances and open new avenues of treatment for sleep disorders and related disorders.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Figure 4 Genetic architectures shared between sleep duration, insomnia symptoms or excessive daytime sleepiness and 20 behavioral and disease traits. LD score regression 67 estimates of genetic correlation (r g ) were obtained by comparing our GWAS findings for sleep duration, insomnia symptoms and excessive daytime sleepiness with summary statistics from 20 publicly available GWAS for psychiatric and metabolic disorders, immune diseases and other traits of natural variation. Blue, positive genetic correlation; red, negative genetic correlation; r g values are displayed for significant correlations. Larger squares correspond to more significant P values. Genetic correlations that were significantly different from zero after Bonferroni correction are marked (*P < 1 × 10 −3 , **P < 1 × 10 −5 , ***P < 1 × 10 −7 ); the P-value cutoff after Bonferroni correction was 0.0025. All genetic correlations in this report can be found in tabular form in supplementary table 12 . BMI, body mass index; BMD, bone mineral density, HOMA-IR, homeostatic model assessment of insulin resistance.
association analysis, we applied the CPASSOC package developed by Zhu et al. 51 to combine association evidence for chronotype, sleep duration, insomnia symptoms and excessive daytime sleepiness. CPASSOC provides two statistics, SHom and SHet. SHom is similar to statistics generated by the fixed-effects meta-analysis method 90 but accounts for the correlation of summary statistics due to trait correlation. SHom uses the sample size for a trait as a weight instead of variance, so that it is possible to combine traits with different measurement scales. SHet is an extension of SHom, but power can be improved when the genetic effect sizes are different for different traits. The distribution of SHet values under the null hypothesis of no association was obtained through an estimated beta distribution. To calculate the SHom and Shet statistics, a correlation matrix is required to account for the correlation among traits or resulting from overlapping or related samples from different cohorts. In this study, we directly provide the correlation matrix calculated from the residuals of four sleep traits after adjusting for age, sex, principal components of ancestry and genotyping array. Post-GWAS genome-wide genetic correlation analysis by LD score regression (LDSC) 67 was conducted using all UK Biobank SNPs also found in HapMap 3 (ref. 89 ) and included publicly available data from 20 published GWAS, using a significance threshold of P = 0.0026 after Bonferroni correction for all 20 tests performed. As expected, the observed heritability estimates from LDSC 67 using summary statistics for HapMap 3 were lower (5.7% (0.0065%) for sleep duration, 13.3% (0.0123%) for insomnia symptoms and 5.3% (0.005%) for sleepiness) than those calculated by BOLT-REML 48 using primary data (10.3% (0.006%) for sleep duration, 20.6% (0.011%) for insomnia symptoms and 8.4% (0.006%) for sleepiness) because the HapMap 3 panel was restricted to variants with MAF >5%. LDSC estimates genetic correlation between two traits (ranging from −1 to 1) from summary statistics using the facts that the GWAS effect size estimate for each SNP incorporates the effects of all SNPs in linkage disequilibrium with that SNP, SNPs with high linkage disequilibrium have higher χ 2 statistics than SNPs with low linkage disequilibrium, and a similar relationship is observed when single-study test statistics are replaced with the product of the z scores from two studies of traits with some correlation 67 . Furthermore, genetic correlation is possible between case-control studies and studies of quantitative traits, as well as within these study types. We performed a weighted GRS analysis using risk scores for RLS, schizophrenia, BMI and fasting insulin. Risk score SNPs passed the genome-wide significance threshold (P < 5 × 10 −8 ) in recent large-scale GWAS and were present in the UK Biobank (RLS, 7 SNPs 65 , Supplementary . Independent SNPs were identified, and β estimates were recorded for calculation of the weighted risk score. The GRS was calculated by summing the products of the risk allele count multiplied by the effect reported in the discovery GWAS. The additive genotype model was used for all SNPs. We performed partitioning of heritability using the 25 precomputed functional annotations available through LDSC, which were curated from large-scale robust data sets 50 . Enrichment both in functional regions and in an expanded region (+500 bp) around loci corresponding to each functional class was calculated to prevent the estimates from being biased upward by enrichment in nearby regions. The multiple-testing threshold was determined using conservative Bonferroni correction (P = 0.05/25 classes).
Data availability. Summary GWAS statistics will be made available at the UK Biobank website (http://biobank.ctsu.ox.ac.uk/).
